Product Development Research Review Council
Kelly Bolton, M.D., Ph.D.
Department of Medicine, Division of Oncology
Dr. Bolton is an assistant professor in the stem cell biology division at Washington University School of Medicine. She has a PhD in genetic epidemiology from Cambridge University. She attended medical school at UCLA School of Medicine. Her research focuses on translational computational genetics in oncology. Her research group uses genomics to define patient populations at high risk for development of malignancies through next generation and the development of molecularly-targeted prevention protocols..
Renzo Canetta, M.D.
During his early years at the Istituto Nazionale Tumori in Milan, Italy (1974-1980), Dr. Canetta’s focus was on clinical trials in lymphomas and gastrointestinal tumors, among others. Since joining Bristol-Myers Squibb (BMS) in 1980, Dr. Canetta has held numerous roles of increasing responsibility and leadership, including head of clinical cancer research; head of development, life cycle management; vice president, oncology global clinical research; and, finally, as vice president, global R&D oncology policy. His experience can be summarized with the introduction of 18 new BMS drugs to the general medical use (two outside of oncology) and the approval of over 50 regulatory dossiers for additional indications/formulations, including some outside of oncology. Dr. Canetta retired from BMS on August 14, 2015 and currently consults/cooperates with non-for-profit organizations, government agencies and professional societies.
Roy Cosan, B.B.A.
Roy Cosan is President of Renova Therapeutics. Prior to joining Renova, he was a Managing Director at Fjord Ventures. Roy’s experience includes 32 years with Johnson and Johnson. He was Vice President of New Product Development at Janssen Pharmaceuticals where he launched Risperdal and Reminyl.
Roy was also a Vice President with the Johnson & Johnson Development Corp., the venture capital arm of J&J where he invested in 19 companies and held 11 board of director seats. Roy helped build a virtual R&D capability within J&J Pharma. He holds a B.B.A. with a concentration in marketing from Western Michigan University.
Jack Geltosky, Ph.D.
JEG and Associates, LLC
Jack has over 30 years of experience in the pharmaceutical industry, evenly split between R&D and licensing.
Jack was the Senior Vice President of Business Development for Arizona Technology Enterprises (AZTE), the technology transfer arm of Arizona State University, from 2007 to June of 2011. He now serves as a Senior Consultant to AZTE. Jack has been a part of CPRIT for seven years, the last two serving as Chairman of the Product Development Review Council.
Jack served on the Board of Directors of Enzon Pharmaceuticals from 2008-2009 and is currently on the Board of Sophiris Bio.
Ginette Serrero, Ph.D.
CEO, A&G Pharmaceutical Inc.
Adjunct Professor, University of Maryland School of Pharmacy & University of Maryland School of Medicine
Ginette is CEO of A&G Pharmaceutical, a company developing novel targets in Oncology which she co-founded in 2000 based on her discovery of the GP88/PGRN growth factor protein and her pioneering research demonstrating its importance in the tumorigenesis of many cancers.
Under her leadership, A&G has advanced several new therapeutic and diagnostic product candidates into preclinical and clinical development, including two breast cancer diagnostics. In particular, a tissue test that measures GP88 in tumor biopsies as predictor of risk of recurrence in early stage breast cancer patients will be commercialized in Q3 2014.
David Shoemaker, Ph.D.
Senior Vice President, Research and Development
David is currently responsible for developing and executing integrated product development strategies for products ranging from discovery through market approval. David serves as an advisor to multidisciplinary program teams, contributing regulatory perspectives on clinical, preclinical, and chemistry, manufacturing and controls development decisions.
David has participated in the development of the regulatory strategy for programs involving central nervous system products, blood products, oncology therapeutics and vaccines, gene and stem cell products, immunomodulators, cardiovascular therapeutics, and metabolic and endocrine therapeutics.
Kristine Swiderek, Ph.D.
Chief Scientific Officer
Dr. Kristine Swiderek is Chief Scientific Officer at Mozart Therapeutics, a company that discovers and develops biologics to target a novel T cell network of pathogenic CD4 and cytolytic-regulatory CD8 T cells to establish immune balance in autoimmune and inflammatory disease.
Prior to joining Mozart Tx, Dr. Swiderek was Senior VP of Research at Alpine Immune Sciences and instrumental in building a pipeline and advancing protein-based immunotherapies for autoimmune disease and cancer. As Chief Scientific Officer at OncoResponse and Theraclone, she was responsible for leading the development of the I-STARTM antibody discovery platform yielding multiple clinical candidates.
She has over 25 years of research and leadership experience in the biopharmaceutical industry and a proven track record of forming successful R&D partnerships and of discovering and advancing a wide variety of protein therapeutic candidates into the clinic.
Colin Turnbull, Ph.D.
Colin Turnbull Consulting LLC
Colin Turnbull is a native of Edinburgh, Scotland. He obtained a Bachelor’s degree in Pharmacy from Heriot-Watt University, Edinburgh, and a Ph.D. in Organic Chemistry from Aston University, Birmingham, England, the subject of his Doctoral thesis being the synthesis and chemical characterization of novel anti-tumor triazenes.
His career in the pharmaceutical industry spanned some 28 years during which he held increasingly senior positions in general management, Health Economics, and Clinical Research, culminating in his appointment as Vice President and Head of Global Oncology Clinical Research, Schering-Plough Research Institute (SPRI), and Chairman, Oncology Development Team, SPRI.
For the last 12 years, Dr. Turnbull has been an independent consultant specializing in carrying out due diligence assessment of oncology related investment opportunities for pharmaceutical and biotechnology industry clients and for venture capital firms.